Department of Internal Medicine, Hotel-Dieu, CHU, Clermont-Ferrand, France.
Intern Med J. 2011 Feb;41(2):202-5. doi: 10.1111/j.1445-5994.2010.02384.x.
Serum sickness may occur in patients treated with chimeric monoclonal antibody. Rituximab, an anti-CD20 chimeric monoclonal antibody, is used with increasing frequency in chronic immune thrombocytopenic purpura (ITP). Rituximab is relatively safe; however, serum sickness is reported in 1-20% of patients, more commonly among those with autoimmune conditions. We describe a case of serum sickness in a patient with ITP and review the literature of rituximab-induced serum sickness.
血清病可能发生在接受嵌合单克隆抗体治疗的患者中。利妥昔单抗，一种抗 CD20 嵌合单克隆抗体，在慢性免疫性血小板减少性紫癜（ITP）中的应用越来越频繁。利妥昔单抗相对安全；然而，有 1-20%的患者会出现血清病，在自身免疫性疾病患者中更为常见。我们描述了一例 ITP 患者的血清病，并复习了利妥昔单抗诱导的血清病的文献。
